Ofatumumab placebo clinical trials

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

This study looks at two new medicines, ofatumumab and siponimod, for children and teenagers aged 10-17 with multiple sclerosis (MS). It compares them to a medicine called fingolimod to see if they are safe and work well.